Wet Age-Related Macular Degeneration Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | IVERIC bio, Ribomic, Curacle, Bio-Thera

Wet Age-Related Macular Degeneration Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | IVERIC bio, Ribomic, Curacle, Bio-Thera
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Wet Age-Related Macular Degeneration pipeline constitutes 75+ key companies continuously working towards developing 80+ Wet Age-Related Macular Degeneration treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Wet Age-Related Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Wet Age-Related Macular Degeneration Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Wet Age-Related Macular Degeneration Market.

 

Some of the key takeaways from the Wet Age-Related Macular Degeneration Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Wet Age-Related Macular Degeneration treatment therapies with a considerable amount of success over the years. 

  • Wet Age-Related Macular Degeneration companies working in the treatment market are Neuracle Genetics, Inc, EyePoint Pharmaceuticals, Inc., RemeGen Co., Ltd., Outlook Therapeutics, Sinocelltech Ltd., Mabwell (Shanghai) Bioscience, 4D Molecular Therapeutics, Michel Giunta, Bio-Thera Solutions, Sylentis, S.A., Shanghai Henlius Biotech, Adverum Biotechnologies, Inc., Ocular Therapeutix, Inc., Clearside Biomedical, Inc., Skyline Therapeutics, AsclepiX Therapeutics, Novartis, Shanghai Refreshgene Tech, Hangzhou Jiayin Biotech Ltd, TOT Biopharm Co., Ltd., Hoffmann-La Roche, Genentech, Inc., Innovent Biologics (Suzhou) Co. Ltd., AO GENERIUM, Bayer, and others, are developing therapies for the Wet Age-Related Macular Degeneration treatment 

  • Emerging Wet Age-Related Macular Degeneration therapies in the different phases of clinical trials are-NG101 AAV gene therapy, Eyp-1901, RC28-E, bevacizumab, Ranibizumab, MW02, 4D-150 IVT, Aflibercept, BAT5906 injection, SYL1801, HLX04-O, ADVM-022, OTX-TKI (axitinib implant), CLS-AX, SKG0106, AXT107, Iptacopan (LNP023), RRG001, EXG102-031, TAB014, Faricimab, LUCENTIS (ranibizumab injection), Aflibercept Ophthalmic, GNR-067, BAY86-5321, and others are expected to have a significant impact on the Wet Age-Related Macular Degeneration market in the coming years.   

  • In December 2023, EyePoint Pharmaceuticals, a US-based pharmaceutical company, has announced positive topline results from the Phase II DAVIO 2 clinical trial of EYP-1901, its investigational sustained delivery maintenance therapy for wet age-related macular degeneration (wet AMD). This controlled, randomized trial compared EYP-1901 to an aflibercept control in 160 wet AMD patients who had previously received standard-of-care anti-vascular endothelial growth factor (VEGF) therapy.

  • In August 2023, Last month in Sacramento, ophthalmologists at UC Davis Health administered an experimental gene therapy to a patient with wet age-related macular degeneration (wet AMD). This marked the first use of gene therapy at the UC Davis Eye Center. The treatment is part of a randomized, partially masked, controlled phase 3 clinical trial evaluating the efficacy and safety of ABBV-RGX-314 for wet AMD. UC Davis Health is among 93 sites in the U.S. participating in the trial. This investigational therapy has not yet been FDA approved, and its efficacy and safety are still being evaluated.

 

Wet Age-Related Macular Degeneration Overview

Wet Age-Related Macular Degeneration (Wet AMD) is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It occurs when abnormal blood vessels grow under the macula, the part of the retina responsible for sharp, central vision. 

 

Get a Free Sample PDF Report to know more about Wet Age-Related Macular Degeneration Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight

 

Emerging Wet Age-Related Macular Degeneration Drugs Under Different Phases of Clinical Development Include:

  • NNG101 AAV gene therapy: Neuracle Genetics, Inc

  • Eyp-1901: EyePoint Pharmaceuticals, Inc.

  • RC28-E: RemeGen Co., Ltd.

  • bevacizumab: Outlook Therapeutics

  • Ranibizumab: Sinocelltech Ltd.

  • MW02: Mabwell (Shanghai) Bioscience

  • 4D-150 IVT: 4D Molecular Therapeutics

  • Aflibercept: Michel Giunta

  • BAT5906 injection: Bio-Thera Solutions

  • SYL1801: Sylentis, S.A.

  • HLX04-O: Shanghai Henlius Biotech

  • ADVM-022: Adverum Biotechnologies, Inc.

  • OTX-TKI (axitinib implant): Ocular Therapeutix, Inc.

  • CLS-AX: Clearside Biomedical, Inc.

  • SKG0106: Skyline Therapeutics

  • AXT107: AsclepiX Therapeutics

  • Iptacopan (LNP023): Novartis

  • RRG001: Shanghai Refreshgene Tech

  • EXG102-031: Hangzhou Jiayin Biotech Ltd

  • TAB014: TOT Biopharm Co., Ltd.

  • Faricimab: Hoffmann-La RocheLUCENTIS (ranibizumab injection): Genentech, Inc.

  • Aflibercept Ophthalmic: Innovent Biologics (Suzhou) Co. Ltd.

  • GNR-067: AO GENERIUM

  • BAY86-5321: Bayer

 

Wet Age-Related Macular Degeneration Route of Administration

Wet Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Wet Age-Related Macular Degeneration Molecule Type

Wet Age-Related Macular Degeneration Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Wet Age-Related Macular Degeneration Pipeline Therapeutics Assessment

  • Wet Age-Related Macular Degeneration Assessment by Product Type

  • Wet Age-Related Macular Degeneration By Stage and Product Type

  • Wet Age-Related Macular Degeneration Assessment by Route of Administration

  • Wet Age-Related Macular Degeneration By Stage and Route of Administration

  • Wet Age-Related Macular Degeneration Assessment by Molecule Type

  • Wet Age-Related Macular Degeneration by Stage and Molecule Type

 

DelveInsight’s Wet Age-Related Macular Degeneration Report covers around 80+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Wet Age-Related Macular Degeneration product details are provided in the report. Download the Wet Age-Related Macular Degeneration pipeline report to learn more about the emerging Wet Age-Related Macular Degeneration therapies

 

Some of the key companies in the Wet Age-Related Macular Degeneration Therapeutics Market include:

Key companies developing therapies for Wet Age-Related Macular Degeneration are – IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, and others.

 

Wet Age-Related Macular Degeneration Pipeline Analysis:

The Wet Age-Related Macular Degeneration pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Wet Age-Related Macular Degeneration with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration Treatment.

  • Wet Age-Related Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Wet Age-Related Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet Age-Related Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Wet Age-Related Macular Degeneration drugs and therapies

 

Wet Age-Related Macular Degeneration Pipeline Market Drivers

  • Rise in ageing population, entry of biosimilars, robust pipeline are some of the important factors that are fueling the Wet Age-Related Macular Degeneration Market.

 

Wet Age-Related Macular Degeneration Pipeline Market Barriers

  • However, burden of medical treatment, high cost associated with antiVEGF agents, decrease in quality of life and other factors are creating obstacles in the Wet Age-Related Macular Degeneration Market growth.

 

Scope of Wet Age-Related Macular Degeneration Pipeline Drug Insight    

  • Coverage: Global

  • Key Wet Age-Related Macular Degeneration Companies: Neuracle Genetics, Inc, EyePoint Pharmaceuticals, Inc., RemeGen Co., Ltd., Outlook Therapeutics, Sinocelltech Ltd., Mabwell (Shanghai) Bioscience, 4D Molecular Therapeutics, Michel Giunta, Bio-Thera Solutions, Sylentis, S.A., Shanghai Henlius Biotech, Adverum Biotechnologies, Inc., Ocular Therapeutix, Inc., Clearside Biomedical, Inc., Skyline Therapeutics, AsclepiX Therapeutics, Novartis, Shanghai Refreshgene Tech, Hangzhou Jiayin Biotech Ltd, TOT Biopharm Co., Ltd., Hoffmann-La Roche, Genentech, Inc., Innovent Biologics (Suzhou) Co. Ltd., AO GENERIUM, Bayer, and others

  • Key Wet Age-Related Macular Degeneration Therapies: NG101 AAV gene therapy, Eyp-1901, RC28-E, bevacizumab, Ranibizumab, MW02, 4D-150 IVT, Aflibercept, BAT5906 injection, SYL1801, HLX04-O, ADVM-022, OTX-TKI (axitinib implant), CLS-AX, SKG0106, AXT107, Iptacopan (LNP023), RRG001, EXG102-031, TAB014, Faricimab, LUCENTIS (ranibizumab injection), Aflibercept Ophthalmic, GNR-067, BAY86-5321, and others

  • Wet Age-Related Macular Degeneration Therapeutic Assessment: Wet Age-Related Macular Degeneration current marketed and Wet Age-Related Macular Degeneration emerging therapies

  • Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration market drivers and Wet Age-Related Macular Degeneration market barriers 

 

Request for Sample PDF Report for Wet Age-Related Macular Degeneration Pipeline Assessment and clinical trials

 

Table of Contents

1. Wet Age-Related Macular Degeneration Report Introduction

2. Wet Age-Related Macular Degeneration Executive Summary

3. Wet Age-Related Macular Degeneration Overview

4. Wet Age-Related Macular Degeneration- Analytical Perspective In-depth Commercial Assessment

5. Wet Age-Related Macular Degeneration Pipeline Therapeutics

6. Wet Age-Related Macular Degeneration Late Stage Products (Phase II/III)

7. Wet Age-Related Macular Degeneration Mid Stage Products (Phase II)

8. Wet Age-Related Macular Degeneration Early Stage Products (Phase I)

9. Wet Age-Related Macular Degeneration Preclinical Stage Products

10. Wet Age-Related Macular Degeneration Therapeutics Assessment

11. Wet Age-Related Macular Degeneration Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Wet Age-Related Macular Degeneration Key Companies

14. Wet Age-Related Macular Degeneration Key Products

15. Wet Age-Related Macular Degeneration Unmet Needs

16 . Wet Age-Related Macular Degeneration Market Drivers and Barriers

17. Wet Age-Related Macular Degeneration Future Perspectives and Conclusion

18. Wet Age-Related Macular Degeneration Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: